Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature

Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature

Abstract Background Myasthenia gravis (MG) is a rare but life-threatening adverse event of immune checkpoint inhibitors (ICI). Given the limited evidence, data from a large cohort of patients is needed to aid in recognition and management of this fatal complication. Methods We reviewed our instituti...

Full description

Bibliographic Details
Main Authors: Houssein Safa, Daniel H Johnson, Van Anh Trinh, Theresa E Rodgers, Heather Lin, Maria E Suarez-Almazor, Faisal Fa’ak, Chantal Saberian, Cassian Yee, Michael A Davies, Sudhakar Tummala, Karin Woodman, Noha Abdel-Wahab, Adi Diab
Format: Article
Language:English
Published: BMJ Publishing Group 2019-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Myasthenia gravis
Immune checkpoint inhibitors
Nivolumab
Pembrolizumab
Ipilimumab
Immunotherapy
Online Access:http://link.springer.com/article/10.1186/s40425-019-0774-y

Internet

http://link.springer.com/article/10.1186/s40425-019-0774-y

Similar Items